Exact Sciences Corporation
EXAS
株式のランク
#1152
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
株価
$104.91
最終同期: 2026-03-23
時価総額
$20.03B
変化（1日）
0.00%
変化（1年）
67.24%
国
US
取引 Exact Sciences Corporation (EXAS)
カテゴリー
Healthcare
Exact Sciences Corporation（EXAS）の利益
Dec 2025 時点の利益 TTM: $-203.89M
Exact Sciences Corporation の最新の財務報告によると、同社の現在の利益は $-203.89M です。2024 年には $-1.04B の利益を上げ、これは 2023 年の利益 $-201.75M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Exact Sciences Corporation の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-203.89M | -3.83% |
| 2025 | $-212.01M | -79.54% |
| 2024 | $-1.04B | 413.60% |
| 2023 | $-201.75M | -68.11% |
| 2022 | $-632.57M | -24.92% |
| 2021 | $-842.51M | 1.62% |
| 2020 | $-829.06M | 103.98% |
| 2019 | $-406.44M | 132.18% |
| 2018 | $-175.06M | 52.78% |
| 2017 | $-114.58M | -31.47% |
| 2016 | $-167.21M | 5.96% |
| 2015 | $-157.80M | 57.73% |
| 2014 | $-100.05M | 115.09% |
| 2013 | $-46.51M | -11.27% |
| 2012 | $-52.42M | 82.81% |
| 2011 | $-28.68M | 148.14% |
| 2010 | $-11.56M | 26.60% |
| 2009 | $-9.13M | -6.29% |
| 2008 | $-9.74M | -18.55% |
| 2007 | $-11.96M | -7.40% |
| 2006 | $-12.92M | -11.05% |
| 2005 | $-14.52M | -21.61% |
| 2004 | $-18.52M | -34.64% |
| 2003 | $-28.34M | -5.16% |
| 2002 | $-29.88M | -99.87% |
| 2001 | $-23.49B | 176,087.09% |
| 2000 | $-13.33M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.61B | -3,831.95% |
US
|
|
| $4.76B | -2,435.60% |
US
|
|
| $-252.70M | 23.94% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -913.19% |
US
|
